Prior to launching any new product on the market, it’s important to evaluate its safety, especially for those products that will come into direct contact with the skin. The Human Repeat Insult Patch Test (HRIPT or RIPT test) is considered the gold standard for in vivo safety assessment, ensuring that tested products do not cause skin irritation or induce skin sensitivity. Additionally, conducting an HRIPT study allows to evaluate the potential allergenicity of tested product and is a crucial safety study to support the hypoallergenic claim.
For those in the cosmetics or personal care product industry, conducting safety evaluations through clinical testing, such as HRIPT, becomes an essential aspect of both product development and regulatory compliance.
Zurko Research HRIPT-RIPT testing capabilities
At Zurko Research, our commitment to our clients and their consumers is steadfast. Through a wide range of safety clinical studies, including HRIPT, we strive to identify any potential irritation or sensitization issues, thus minimizing the risk of adverse reactions for consumers and ensuring the success of our clients. Furthermore, our commitment to excellence is reflected in the meticulous approach we take in Human Repeat Insult Patch Test (HRIPT) studies. Our protocol consists of three different phases, ensuring a comprehensive evaluation of products that come into direct contact with the skin.
Product claims supported by HRIPT/RIPT studies
Products that can be subjected to HRIPT/RIPT
publi editorial
International Business Manager
jacob@zurkoresearch.com
Ph. +34 91 521 15 88
Avda. De la Osa Mayor,
4 28023 Madrid, Spain
Founded in Mauritius in 2004, providing a full suite of services. These services range from…
Skinobs Revamps “We Are Testing” with a bold new identity and website ahead of NYSCC…
👉 The Skinobs team will be delighted to welcome you booth 857, to talk with…